Pharmacodynamic consequences of administration of VLA-4 antagonist CDP323 to multiple sclerosis subjects: a randomized, double-blind phase 1/2 study.

Lymphocyte inhibition by antagonism of α4 integrins is a validated therapeutic approach for relapsing multiple sclerosis (RMS).Investigate the effect of CDP323, an oral α4-integrin inhibitor, on lymphocyte biomarkers in RMS.Seventy-one RMS subjects aged 18-65 years with Expanded Disability Status Sc...

Ausführliche Beschreibung

Bibliografische Detailangaben

Hauptverfasser:	Christian Wolf, Jagdev Sidhu, Christian Otoul, Dexter L Morris, Jennifer Cnops, Jorg Taubel, Barbara Bennett
Format:	Artigo
Sprache:	Inglês
Veröffentlicht:	Public Library of Science (PLoS) 2013-01-01
Schriftenreihe:	PLoS ONE
Online-Zugang:	http://europepmc.org/articles/PMC3589412?pdf=render
Tags:	Tag hinzufügen Keine Tags, Fügen Sie das erste Tag hinzu!